News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BaroFold, Inc. Grants Exclusive License for Interferon Beta Products Developed Using PreEMT(TM) Technology to Nuron Biotech


5/17/2010 9:21:03 AM

AURORA, Colo.--(BUSINESS WIRE)--BaroFold, Inc. today announced that it has entered into an agreement to exclusively license its PreEMT™ Technology to Nuron Biotech for the development of BaroFeron™ and follow-on interferon beta products. BaroFeron is a proprietary recombinant human interferon beta being developed for the treatment of multiple sclerosis. Specific terms of the agreement are not disclosed.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES